MS and Demyelinating Disorders

Latest News

Latest Videos

High-Efficacy Therapy for a 35-Year-Old Man With Relapsing MS

Factors That Influence Practice Effects: Stephen Rao, PhD, ABPP-Cn

Gene Therapy in SLC13A5 Deficiency, DMTs Reduce Risk of Disability in Pediatric MS, FASTEST Phase 3 Study Announced

Evaluating, Expanding on Responsive Neurostimulation in Older Adults: Vineet Punia, MD, MS

Advice for Managing MS

Improving Progressive MS Research: Kathy Zackowski, PhD, OTR

Leaving a Nebulous State of Care for Patients With NMOSD: Bruce Cree, MD, PhD

Better Defining Multiple Sclerosis Categorization: Daniel Ontaneda, MD, PhD

Clinical Utility of Manual Dexterity Test in MS: Marisa McGinley, DO

Impressions of a 35-Year-Old Man With Relapsing MS

CME Content

Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Video

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

Video

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

Audio

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

Audio

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

More News

Role of Ozanimod in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

Role of Diroximel Fumarate in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

Role of Ocrelizumab in Europe for Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

Ocrelizumab for the Treatment of Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

Role of Siponimod in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

Treating With Cladribine in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

Clinical Trials for Cladribine in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

The Use of Glatiramer Acetate in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

The Use of Interferon in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

First-Line Therapies for Relapsing Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

Clinically Isolated Syndrome Versus Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

MOG-IgG in Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

Differential Diagnosis of Multiple Sclerosis

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

Diagnosis of Multiple Sclerosis: The McDonald Criteria

BySven Meuth, MD, PhD,Patricia Coyle, MD,Wallace Brownlee, MBChB, PhD, FRACP,Fred D. Lublin, MD

September 3rd 2020

Closing the Treatment Gap in Progressive MS

ByTori Rodriguez, MA

August 29th 2020

New biomarkers of disease activity may help better vet investigational therapies aimed at slowing the insidious neurodegeneration seen in primary progressive multiple sclerosis.

FDA Approves Ofatumumab, EVT Effective in Late Presenting Stroke, Rimegepant Safe With CGRP Antibodies

ByNeurologyLive® Staff

August 29th 2020

Neurology News Network for the week ending August 29, 2020.

NeurologyLive Friday 5 - August 28, 2020

ByNeurologyLive® Staff

August 28th 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 28, 2020.

Approaching Multiple Sclerosis With a Global Perspective

ByMatt Hoffman

August 26th 2020

A group of international experts in the treatment of multiple sclerosis offer their varying viewpoints on the history, identification, and management of the disease.

Satralizumab Approved, Epilepsy Surgery Cost-Effective, FDA Approves DMD Treatment Viltolarsen

ByNeurologyLive® Staff

August 22nd 2020

Neurology News Network for the week ending August 22, 2020.

NeurologyLive Friday 5 — August 21, 2020

ByNeurologyLive® Staff

August 21st 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 21, 2020.

Ofatumumab FDA-Approved for Relapsing Multiple Sclerosis Treatment

ByMatt Hoffman

August 20th 2020

Novartis’ anti-CD20 monoclonal antibody ofatumumab (Kesimpta) is administered once monthly at home, and is expected to be available for those with multiple sclerosis as early as September 2020.

Satralizumab Approved for Treatment of Neuromyelitis Optica Spectrum Disorder

ByAlicia Bigica

August 15th 2020

The subcutaneous injection is indicated in patients with anti-aquaporin-4 antibody positive NMOSD.

Aducanumab BLA Accepted, Risdiplam Receives FDA Approval, Ofatumumab Lower ARRs Than Teriflunomide

ByNeurologyLive® Staff

August 15th 2020

Neurology News Network for the week ending August 15, 2020.

NeurologyLive Friday 5 — August 14, 2020

ByNeurologyLive® Staff

August 14th 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 14, 2020.

Personal Social Networks Associated With Physical Function in Multiple Sclerosis

ByMarco Meglio

August 12th 2020

Larger social network effective size correlated with better physical function, while network constraint correlated with worse physical function in those with multiple sclerosis.

MS and Demyelinating Disorders

Latest News

Latest Videos

High-Efficacy Therapy for a 35-Year-Old Man With Relapsing MS

Factors That Influence Practice Effects: Stephen Rao, PhD, ABPP-Cn

Gene Therapy in SLC13A5 Deficiency, DMTs Reduce Risk of Disability in Pediatric MS, FASTEST Phase 3 Study Announced

Evaluating, Expanding on Responsive Neurostimulation in Older Adults: Vineet Punia, MD, MS

Advice for Managing MS

Improving Progressive MS Research: Kathy Zackowski, PhD, OTR

Leaving a Nebulous State of Care for Patients With NMOSD: Bruce Cree, MD, PhD

Better Defining Multiple Sclerosis Categorization: Daniel Ontaneda, MD, PhD

Clinical Utility of Manual Dexterity Test in MS: Marisa McGinley, DO

Impressions of a 35-Year-Old Man With Relapsing MS

CME Content

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

More News

Role of Ozanimod in Multiple Sclerosis

Role of Diroximel Fumarate in Multiple Sclerosis

Role of Ocrelizumab in Europe for Multiple Sclerosis

Ocrelizumab for the Treatment of Multiple Sclerosis

Role of Siponimod in Multiple Sclerosis

Treating With Cladribine in Multiple Sclerosis

Clinical Trials for Cladribine in Multiple Sclerosis

The Use of Glatiramer Acetate in Multiple Sclerosis

The Use of Interferon in Multiple Sclerosis

First-Line Therapies for Relapsing Multiple Sclerosis

Clinically Isolated Syndrome Versus Multiple Sclerosis

MOG-IgG in Multiple Sclerosis

Differential Diagnosis of Multiple Sclerosis

Diagnosis of Multiple Sclerosis: The McDonald Criteria

Closing the Treatment Gap in Progressive MS

FDA Approves Ofatumumab, EVT Effective in Late Presenting Stroke, Rimegepant Safe With CGRP Antibodies

NeurologyLive Friday 5 - August 28, 2020

Approaching Multiple Sclerosis With a Global Perspective

Satralizumab Approved, Epilepsy Surgery Cost-Effective, FDA Approves DMD Treatment Viltolarsen

NeurologyLive Friday 5 &mdash; August 21, 2020

Ofatumumab FDA-Approved for Relapsing Multiple Sclerosis Treatment

Satralizumab Approved for Treatment of Neuromyelitis Optica Spectrum Disorder

Aducanumab BLA Accepted, Risdiplam Receives FDA Approval, Ofatumumab Lower ARRs Than Teriflunomide

NeurologyLive Friday 5 &mdash; August 14, 2020

Personal Social Networks Associated With Physical Function in Multiple Sclerosis

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis

Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers

Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis

Using Human iPSC Models to Dissect PIRA Mechanisms in Progressive Multiple Sclerosis: Valentina Fossati, PhD

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib

NeurologyLive Friday 5 — August 21, 2020

NeurologyLive Friday 5 — August 14, 2020